# Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

> **NCT06360289** · — · RECRUITING · sponsor: **Alnylam Pharmaceuticals** · enrollment: 500 (estimated)

## Conditions studied

- Hereditary Amyloidosis, Transthyretin-Related
- Asymptomatic Carrier State

## Interventions

- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT06360289
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-25
- **Primary completion:** 2027-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360289, "Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06360289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*